Finanzas de Bio-Techne Corp (TECH)TECHBio-Techne Corp

Bio-Techne Corporation (TECH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables, accounting for 82.6% of total sales, equivalent to $257.34M. Other significant revenue streams include Instruments and Service. Understanding this composition is critical for investors evaluating how TECH navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Bio-Techne Corporation maintains a gross margin of 66.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 27.85%, while the net margin is 17.01%. These profitability ratios, combined with a Return on Equity (ROE) of 9.03%, provide a clear picture of how effectively TECH converts its operational activities into shareholder value.

In the context of the broader market, TECH competes directly with industry leaders such as SMMT and ELAN. With a market capitalization of $11.39B, it holds a significant position in the sector. When comparing efficiency, TECH's gross margin of 66.02% stands against SMMT's N/A and ELAN's 48.17%. Such benchmarking helps identify whether Bio-Techne Corporation is trading at a premium or discount relative to its financial performance.

The company's net profit for Q4 FY2026 was $54.622 million, translating to $0.35 per share, a significant recovery from a loss of $17.677 million in the same quarter last year. Gross margin remains strong at 66.02%.